Female participants showed slightly higher nausea rates (31% versus 24%), which is consistent with whats observed across other GLP-1 class compounds
"ok so went shopping to (buy) a comfy lounge wear outfit for my 22 hour flight to australia- was undecided as i cant see myself in this new smaller body," O'Donnell wrote in her caption
Eligible patients may discuss physician-supervised tirzepatide, semaglutide, nutrition planning, gradual dose adjustments, side-effect management, and regular follow-up care
Lowering blood sugar Stimulating insulin release when glucose levels are high while also reducing glucagon secretion to prevent excess sugar production by the liver
Eligibility is determined through clinical screening, and not all applicants will qualify
Expected Approval Timeline Retatrutide is still in clinical development